Fresenius Medical Care AG
Could not find a ticker for this position, may be a filing error
A maker of kidney-dialysis machines, filters, and clinics, Fresenius Medical Care helps people with kidney failure get life-sustaining dialysis treatment at its Fresenius Kidney Care centers and at home. Its roots go back to a German pharmacy founded in 1912, and the company was born in 1996 when that firm's dialysis business merged with the American care provider National Medical Care. The Fresenius name itself comes from the pharmacist Eduard Fresenius, who started the original company from the historic Hirsch (Deer) Pharmacy in Frankfurt.
American Depositary Shares (ADS), each representing one ordinary share, listed on NYSE
Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: On August 20, 2026, Fresenius KGaA entered into the Share Purchase Agreement (as defined in Item 6) and agreed to sell certain Shares (as defined in Item 6) representing in the aggregate up to approximately 2.97% of the total share capital of the Company to the Purchaser in a block trade in accordance with the terms of the Share Purchase Agreement, as further described below. Fresenius KGaA is entering into this transaction as part of its broader portfolio optimization strategy. Fresenius KGaA intends to review its investment in the Company on a continuing basis and, depending on market conditions, the trading price of the Shares, legal or regulatory developments and other factors, may from time to time consider or pursue alternatives with respect to such investment as it deems appropriate, including derivative or other transactions referencing the Shares. Fresenius KGaA may also determine not to pursue any such alternatives and may change its intentions with respect to any of the foregoing.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Fresenius SE & Co. KGaA | 13D/AActivist | 25.6% | 67.18M | Aug 24, 2026 |
Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: On August 20, 2026, Fresenius KGaA entered into the Share Purchase Agreement (as defined in Item 6) and agreed to sell certain Shares (as defined in Item 6) representing in the aggregate up to approximately 2.97% of the total share capital of the Company to the Purchaser in a block trade in accordance with the terms of the Share Purchase Agreement, as further described below. Fresenius KGaA is entering into this transaction as part of its broader portfolio optimization strategy. Fresenius KGaA intends to review its investment in the Company on a continuing basis and, depending on market conditions, the trading price of the Shares, legal or regulatory developments and other factors, may from time to time consider or pursue alternatives with respect to such investment as it deems appropriate, including derivative or other transactions referencing the Shares. Fresenius KGaA may also determine not to pursue any such alternatives and may change its intentions with respect to any of the foregoing. | ||||
| BlackRock, Inc. | 13GPassive | 5% | 13.45M | Jul 28, 2026 |
| HARRIS ASSOCIATES L P | 13G/APassive | 3.9% | 11.72M | Feb 14, 2025 |
| Harris Associates, Inc. | 13G/APassive | 3.9% | 11.72M | Feb 14, 2025 |